Fortune writer John Simons opines that a rumored [0] merger of Pfizer and Wyeth would be all wrong for both companies. In his view, a merger would amount to a marriage [1] of weaknesses [1]. Pfizer needs blockbusters to overcome looming patent expirations and Wyeth has recently been failing to deliver.

"Would the idea behind the merger be that misery loves company?" says Standard & Poors pharma analyst Herman Saftlas. "Most mergers in this sector haven't panned out from an earnings growth perspective. But even worse, these two companies are in the same boat."

- read Simon's opinion piece [2]

Related Articles:
Wyeth buyout a good deal for Pfizer? Report [2]
What's next for Pfizer? Report [3]
Wyeth stumbles badly trying to develop new drugs. Report [4]